Startups channel feed – Endpoints News

Startups channel feed

Replimune adds a $55M round and some expert help as it pursues next-gen oncolytics R&D

8 years ago

Google helps boost Gritstone’s neoantigen R&D gamble to $195M as researchers prep for first human study

8 years ago

Big names, big companies back a cell therapy startup run by a high-profile regenerative med expert

8 years ago

The big revamp at GlaxoSmithKline R&D includes a new collaboration on AI

8 years ago

Orbimed partner in search of a cure for Parkinson’s launches new gene therapy player

8 years ago

SoftBank bets $1.1B on Roivant CEO Vivek Ramaswamy’s brash new biotech strategy

8 years ago

Amplyx grabs $67M to fund a pivotal drive to the FDA with an anti-fungal aimed at a lethal threat

8 years ago

Milestone Pharma preps a leap into PhIII cardio study with $55M round backed by Novo

8 years ago

A fast-moving entry in the gene editing race is speeding to the clinic, fueled by an $83.5M round

8 years ago

British billionaire Jim Mellon and high-profile partners roll the dice on an anti-aging upstart

8 years ago

Riders on the storm: VenatoRx bags a $42M round to back antibiotics pipeline

8 years ago

Lilly, J&J, AbbVie and WuXi help seed a regenerative medicine upstart

8 years ago

Backed by partners at Pfizer, eFFECTOR brings its VC total to $150M as PhII cancer trial looms

8 years ago

An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business

8 years ago

Big Pharma VCs jump in to back a $63M mission to tackle a genetic driver of Alzheimer’s

8 years ago

Celgene vet Jackie Fouse grabs the reins of a Vivek Ramaswamy vant-up

8 years ago

Google’s data-crunching mavens at GV buy in to Decibel’s R&D program for hearing loss, tinnitus

8 years ago

Medicxi’s new fund jumps off the beaten biotech path to lead a $30M round for diabetes program

8 years ago

With deep ties to China, Vivace exits stealth mode with a lead cancer program, platform and $40M

8 years ago

Versant carefully sets the stage for a $68M debut of a biotech player focused on synthetic lethality

8 years ago

Langer-backed Sigilon sets sail with $23M and new ‘living’ cell therapy tech

8 years ago

Rubius lands $120M bonanza to fund a groundbreaking pipeline effort on a new drug platform

8 years ago

Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals

8 years ago

Little Aziyo is growing a new regenerative med company, led by some familiar faces in the biz

8 years ago

First page Previous page 68 69 707172 73 74 Next page Last page